Mid-year review: notable FDA drug approvals of 2025

As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representing significant advancements in their respective therapeutic areas. 

Journavx (suzetrigine)

Approval date: January 30, 2025

Journavx represents a significant breakthrough as a first-in-class, non-opioid analgesic for the treatment of moderate to severe acute pain in adults. This novel therapy reduces pain by targeting a specific pain-signalling pathway involving sodium channels in the peripheral nervous system, intercepting pain signals before they reach the brain.

The approval of Journavx addresses a critical need for effective pain management alternatives to opioids, potentially offering patients relief without the very real concerns of addiction and other serious side effects associated with those traditional opioid medications.

Blujepa (gepotidacin)

Approval date: March 25, 2025

Blujepa received approval for the treatment of uncomplicated urinary tract infections (UTIs), one of the most common bacterial infections affecting millions annually. As antimicrobial resistance continues to challenge existing treatment options, Blujepa is an important addition to the antibiotic armamentarium.

This approval is particularly significant given the growing concerns about antibiotic resistance in common urinary pathogens, offering clinicians a new and viable tool in managing prevalent infections.

Qfitlia (fitusiran)

Approval date: March 28, 2025

Qfitlia embodies a significant advancement in haemophilia treatment, approved to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A or B. This therapy offers a novel approach to managing these inherited bleeding disorders.

What makes Qfitlia particularly noteworthy is its potential to address the needs of patients regardless of haemophilia type, providing a treatment option that may help reduce the burden of prophylactic therapy while maintaining effective bleeding control.

Imaavy (nipocalimab-aahu)

Approval Date: April 29, 2025

Imaavy received approval for the treatment of generalised myasthenia gravis, an autoimmune neuromuscular disorder characterised by muscle weakness that worsens with activity and improves with rest. This condition can significantly impact daily functioning and quality of life.

The approval of Imaavy provides a new therapeutic option for patients with this challenging condition, potentially offering improved symptom control and enhanced quality of life for those who may not have responded positively to existing treatments.

Emrelis (telisotuzumab vedotin-tllv)

Approval Date: May 14, 2025

Emrelis was approved for the treatment of locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy. This targeted approach addresses a specific molecular subtype of lung cancer.

The approval of Emrelis highlights the continuing evolution toward precision medicine in oncology, offering a targeted option for patients with specific tumour characteristics who have progressed on previous therapies.

Ibtrozi (taletrectinib)

Approval Date: June 11, 2025

Ibtrozi received FDA approval for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This highly selective, next-generation oral ROS1 tyrosine kinase inhibitor addresses a specific molecular subtype of lung cancer.

What distinguishes Ibtrozi is its enhanced ability to penetrate the central nervous system, effectively targeting brain metastases that are common in ROS1-positive NSCLC patients. The approval was based on the TRUST-I and TRUST-II clinical studies, which demonstrated impressive response rates and durability.

Ibtrozi offers improved safety with lower neurological toxicity while maintaining strong efficacy against CNS metastases, providing an important new option for both treatment-naïve patients and those who have developed resistance to earlier generation TKIs.

As we move into the second half of 2025, these approvals reflect the FDA's ongoing commitment to facilitating access to innovative therapies across multiple therapeutic areas. From novel pain management and rare genetic disorders to common infections and complex cancers, these new medications are important additions to the treatment landscape, potentially improving outcomes for patients with significant unmet medical needs.

The pharmaceutical pipeline remains robust, even in the midst of some uncertainty, showing that making life-improving drugs is still the main driver for pharmaceutical companies. There will no doubt surface several more notable approvals before year's end. 

For the major drug approvals of 2024, see here >>>